Reported Thursday, Roche's Genentech Halts SKYSCRAPER-06 Trial After Tiragolumab Plus Tecentriq And Chemotherapy Show Reduced Efficacy Compared To Comparator Arm
Reported Thursday, Roche's Genentech Halts SKYSCRAPER-06 Trial After Tiragolumab Plus Tecentriq And Chemotherapy Show Reduced Efficacy Compared To Comparator Arm
羅氏的亨特西公司週四報告稱，在提拉戈盧瑪膠囊、特喜寧以及化療聯合治療方案的 SKYSCRAPER-06 試驗中，療效相較於對照組有所降低而中止了試驗。
- SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and overall survival at first interim analysis –
- The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy compared to the comparator arm –
- Safety was consistent with previous studies, however we intend to halt the trial due to reduced efficacy compared to the comparator arm –
- SKYSCRAPER-06評估tiragolumab加Tecentriq和化療在主要分析中未達到無進展生存期和在第一次中期分析中的總生存期主要終點—
- 與對照組相比，tiragolumab加Tecentriq和化療的聯合治療效果較差—
- 雖然安全性與以往研究一致，但由於效果不及對照組，我們打算停止該試驗—